US Clinical Lead

John Goldfinch

MBA, CRM, US Clinical Lead

US Clinical Lead, John Goldfinch, brings more than 18 years’ experience in oncology clinical development and project management. In his previous role at Nirogy Therapeutics, he was Senior Director of Project Management, where he managed the lead compound through preclinical and IND development.

Prior to joining Nirogy, John spent 10 years at Athenex, where he served increasing role of responsibility, lastly as the Director of Clinical Operations for the company. John was responsible for managing the global development program of the company’s lead candidate through FDA submission.

He started his career as a Network Project Coordinator at Roswell Park Cancer Center where he was responsible for managing external clinical trials.

AT TILT, John is responsible for advancing TILT’s US clinical program of phase I and II clinical trials, maintaining and initiating contacts with the clinical trial sites, managing CROs, and participating to the regulatory interactions.

John holds an MBA in Healthcare Management from the University of Phoenix and a Post Graduate Certificate in Clinical Research Management from Duke University.

Akseli Hemminki

MD, PhD, eMBA, Founder & CEO and Member of the Board of Directors

Aino Kalervo

MSc, MS, Chief Operating Officer

Kari Varkila

MD, PhD, MBA, Chief Medical Officer

Tuija Keinonen

PhD, Chief Regulatory Officer, Chair of the Board of Directors

Juha Pihlman

BSc, CFO consultant

Suvi Sorsa

PhD, VP of Clinical Affairs

Víctor Cervera-Carrascón

PhD, VP of Business Development

Elina Haavisto

MSc, Head of CMC Regulatory Affairs

Claudia Kistler

PhD, Head of Clinical Operations

Riikka Havunen

PhD, Head of R&D

João Manuel Santos

PhD, Head of Immunology

Cristina Pereira

PhD, Head of Manufacturing

Veera Kukkurainen

MSc, Head of Operations

Henrik Roosvall

Business Operations Manager

James Clubb

MSc, Project Manager

Dafne Quixabeira

MSc, Project Manager

Remi Gloeckler

PhD, CMC Advisor